Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Centro Escolar University (CEU) was once again filled with energy and Escolarian pride as students came together to celebrate the CEU Sportsfest 2025, with ...

CVS Health Corporation ( NYSE: CVS) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial ...

Carson’s Northridge Pharmacy, 4923 Security Drive in Moorefield Twp., will transfer prescriptions to Kroger Pharmacy on Derr Road as of May 9, owner and pharmacist Joti Carson said. The pharmacy ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

A decision is expected in the fourth quarter of 2025.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Once connected, they could receive at-home visits and, in some cases, medication delivery if they’re unable to visit a pharmacy.